Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3297 participants.
Also called NCT01720446
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,297 participants
- Sponsor
- Registry
-
NCT01720446 -
2012-002839-28
-
- Other papers using this trial's data
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Argentina, Australia, Brazil, Bulgaria, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Poland, Russia, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01720446. Randomized; double masking; primary purpose treatment. Start 2013-02-21 (actual); primary completion 2016-03-15 (actual). Results posted on 2018-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™ 6
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01720446- Content hash
991cc507330eb2d94864909807c1e4d5bf9806b62d42863b4408e7123d393f56